Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
219.80
-0.20 (-0.09%)
At close: Feb 5, 2026

DSE:SQURPHARMA Income Statement

Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
81,95276,28870,10160,70857,59850,703
Revenue Growth (YoY)
13.40%8.83%15.47%5.40%13.60%10.52%
Cost of Revenue
42,35240,37737,54832,47328,71925,470
Gross Profit
39,60035,91132,55328,23528,87925,233
Selling, General & Admin
18,15916,75614,57111,68912,11810,034
Other Operating Expenses
-298.05-238.088.1-144.4-98.27-69.57
Operating Expenses
17,86116,51814,57911,54512,0199,965
Operating Income
21,74019,39317,97416,69016,86015,269
Interest Expense
-145.67-214.8-244-118.97-0.03-0.01
Interest & Investment Income
6,7786,2094,6453,9573,0043,137
Earnings From Equity Investments
2,9873,1942,5952,5232,0111,291
Currency Exchange Gain (Loss)
122.14308.43346.52650.1451.3419.42
Other Non Operating Income (Expenses)
-----34.43
EBT Excluding Unusual Items
31,48128,88925,31623,70122,32519,751
Gain (Loss) on Sale of Investments
----384.59177.04
Gain (Loss) on Sale of Assets
-5.04---79.853.49-
Other Unusual Items
0.70.930.260.620.7232.06
Pretax Income
31,47728,89025,31623,62222,76419,960
Income Tax Expense
5,5254,9194,3894,6424,6074,013
Earnings From Continuing Operations
25,95123,97120,92718,98018,15715,947
Minority Interest in Earnings
-3.62-3.12-1.61-0.240.03-
Net Income
25,94823,96820,92618,98018,15715,947
Net Income to Common
25,94823,96820,92618,98018,15715,947
Net Income Growth
15.97%14.54%10.25%4.53%13.86%19.42%
Shares Outstanding (Basic)
886886886886886886
Shares Outstanding (Diluted)
886886886886886886
EPS (Basic)
29.2727.0423.6121.4120.4817.99
EPS (Diluted)
29.2727.0423.6121.4120.4817.99
EPS Growth
15.97%14.54%10.25%4.53%13.86%19.42%
Free Cash Flow
15,03211,12514,3485,6856,6927,178
Free Cash Flow Per Share
16.9612.5516.186.417.558.10
Dividend Per Share
12.00012.00011.00010.50010.0006.000
Dividend Growth
9.09%9.09%4.76%5.00%66.67%34.04%
Gross Margin
48.32%47.07%46.44%46.51%50.14%49.77%
Operating Margin
26.53%25.42%25.64%27.49%29.27%30.11%
Profit Margin
31.66%31.42%29.85%31.26%31.52%31.45%
Free Cash Flow Margin
18.34%14.58%20.47%9.37%11.62%14.16%
EBITDA
23,94021,59420,29319,00018,69517,151
EBITDA Margin
29.21%28.31%28.95%31.30%32.46%33.83%
D&A For EBITDA
2,2002,2012,3192,3101,8351,882
EBIT
21,74019,39317,97416,69016,86015,269
EBIT Margin
26.53%25.42%25.64%27.49%29.27%30.11%
Effective Tax Rate
17.55%17.03%17.34%19.65%20.24%20.10%
Revenue as Reported
----57,59850,703
Advertising Expenses
-8.691.18961.423.613.01
Source: S&P Global Market Intelligence. Standard template. Financial Sources.